RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma.

CONCLUSION: We conclude that RELL1 might serve as a potential therapeutic target or prognostic marker in glioblastoma and diffuse glioma cases.
PMID: 32683297 [PubMed - as supplied by publisher]

Source: International Immunopharmacology - July 15, 2020 Category: Allergy & Immunology Authors: Jin X, Xie H, Liu X, Shen Q, Wang Z, Hao H, Gu Y Tags: Int Immunopharmacol Source Type: research